𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor

✍ Scribed by Shelonitda Rose; Yaqoob Ali; Barbara Maffei; Parvin Saidi

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
237 KB
Volume
82
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Fludarabine, cytarabine, and granulocyte
Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes
✍ Felicetto Ferrara; Franco Leoni; Antonio Pinto; Salvatore Mirto; Enrica Morra; V πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 96 KB πŸ‘ 1 views

## BACKGROUND. The prognosis of patients with high risk myelodysplastic syndromes (MDS) (i.e., refractory anemia with excess of blasts [RAEB] and refractory anemia with excess of blasts in transformation [RAEB-t]) usually is poor. The combination of fludarabine, cytarabine, and granulocyte-colony

Sweet's syndrome associated with sargram
Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment
✍ Geetika Kumar; Jack M. Bernstein; Jill S. Waibel; Michael A. Baumann πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 155 KB πŸ‘ 1 views

## Abstract Sweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation. This complication has not previously been reported during treatment with sargramostim

Treatment with granulocyte-macrophage co
Treatment with granulocyte-macrophage colony stimulating factor and the adult respiratory distress syndrome
✍ Dr. Gregor Verhoef; Marc Boogaerts πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 236 KB πŸ‘ 1 views

We report a case of a patient who developed a fatal adult respiratory distress syndrome (ARDS) during treatment with rh granulocyte-macrophage colony stimulating factor (rhGM-CSF) (250 mcg/m2/day s.c.) and low-dose cytosine-arabinoside (Ara-C) (20 mg/ m2/day s.c.). Several mechanisms which might exp